The GAVI vaccine alliance has stated that the first of nearly 100 million doses of US pharmaceutical company Johnson & Johnson's (J&J) (NYSE:JNJ) COVID-19 vaccine being donated by the European Union by year-end have begun arriving in African countries, Reuters news agency reported on Monday.
GAVI, which leads the COVAX vaccine sharing facility, said that this deal was negotiated as part of the bloc's overall pledge to share at least 500 million doses with low and lower-middle income countries by mid-2022.
Ursula von der Leyen, European Commission president, was quoted as saying: "The first doses have reached Niger, with more doses arriving in a number of countries this week."
The commission's statement also listed Guinea Conakry, Mauritania, the Central African Republic, Djibouti, Nigeria, Togo and the Republic of Congo.
Celltrion's biosimilar EYDENZELT (aflibercept-boav) approved by US FDA
Rigel Pharmaceuticals begins dose expansion phase of R289 study in lower-risk MDS
Precision NeuroMed's glioblastoma multiforme treatment granted FDA Orphan Drug Designation
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
Oxford Biomedica expands US operations with acquisition of viral vector facility in North Carolina
DarioHealth and OneStep partner to integrate fall risk technology into digital health platform
Ananda Pharma achieves key Phase 1 milestone for MRX1 CBD program
Alvotech and Advanz Pharma announce EMA acceptance of AVT23 marketing application
Polarean expands Ascend Imaging partnership to boost US market reach
Alto Neuroscience receives FDA Fast Track designation for ALTO-101
Calico Life Sciences' investigational treatment for ADPKD receives US FDA Fast Track Designation